Boosting Pharmaceutical Innovation in the Post-TRIPS Era

Boosting Pharmaceutical Innovation in the Post-TRIPS Era

Real-Life Lessons for the Developing World

Burcu Kilic

This timely book investigates the concept of innovation and illustrates the crucial role that patent strategies play within processes of pharmaceutical innovation. Drawing on extensive country and company case studies, it identifies the key issues relevant to the revival of local pharmaceutical industries. Based on an understanding of the post-TRIPS environment and case studies of national innovation strategies, it specifically addresses an important question – to what extent can lessons from national experiences be transferred to current policy developments for innovation in the pharmaceutical industry in a developing country context?

Chapter 3: Innovation and the pharmaceutical industry

Burcu Kilic

Subjects: law - academic, biotechnology and pharmaceutical law, intellectual property law

Extract

Innovation in development of drugs is critical to the survival of a big pharmaceutical business model. It follows that innovation in drug development is a fundamental requirement for a company to establish and maintain a competitive advantage in an increasingly complex world. Pharmaceutical innovation has numerous features and is an ongoing process. The scope of innovation generally ranges from developing, manufacturing and marketing new drugs about which relatively little is known at the time of their discovery, to enhancing existing drugs that have been on the market for some time by making minor changes to them. Between these activities, manufacturers also try to find new ways to increase the safety, effectiveness, and convenience of their products. Given the relationship between research and development (R & D), industrial innovation and growth, the analysis of the pharmaceutical industry undertaken here demonstrates an extremely important part of development economics. Co-operation across government, universities and industry often combines to provide a high level of expertise, which accelerates the process of bringing new products to the market. The industry maintains a number of patterns, which are linked to two main factors. The first factor can be identified as the nature of the drug discovery process; these are characterised by a low degree of cumulativeness and by quasi-random search procedures. The fragmented nature of the relevant markets is the second factor that shapes pharmaceutical innovation.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information